Heartland Advisors Inc. acquired a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 83,505 shares of the medical equipment provider’s stock, valued at approximately $5,237,000.
A number of other institutional investors also recently made changes to their positions in SNN. Clearstead Trust LLC bought a new position in shares of Smith & Nephew SNATS during the 2nd quarter valued at $25,000. Addison Advisors LLC bought a new stake in Smith & Nephew SNATS in the second quarter worth $43,000. Allworth Financial LP bought a new stake in Smith & Nephew SNATS in the second quarter worth $48,000. Garner Asset Management Corp purchased a new stake in Smith & Nephew SNATS during the fourth quarter valued at about $27,000. Finally, Arax Advisory Partners boosted its position in Smith & Nephew SNATS by 142.6% during the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 569 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.
Wall Street Analysts Forecast Growth
SNN has been the topic of a number of recent research reports. Weiss Ratings cut Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. Wall Street Zen cut Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Sunday, August 16th. The Goldman Sachs Group restated a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Canaccord Genuity Group decreased their price target on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating on the stock in a research note on Monday, May 11th. Finally, Sanford C. Bernstein set a $31.85 price target on Smith & Nephew SNATS in a research note on Monday, May 11th. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $30.93.
Smith & Nephew SNATS Trading Up 0.9%
Shares of Smith & Nephew SNATS stock opened at $29.29 on Friday. Smith & Nephew SNATS, Inc. has a 12-month low of $28.56 and a 12-month high of $38.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. The company’s fifty day simple moving average is $30.32 and its two-hundred day simple moving average is $31.87.
Smith & Nephew SNATS Announces Dividend
The company also recently announced a dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 2nd will be issued a dividend of $0.312 per share. This represents a dividend yield of 205.0%. The ex-dividend date is Friday, October 2nd.
Smith & Nephew SNATS Company Profile
Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.
In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.
Featured Stories
- Five stocks we like better than Smith & Nephew SNATS
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew SNATS, Inc. (NYSE:SNN – Free Report).
Receive News & Ratings for Smith & Nephew SNATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS and related companies with MarketBeat.com's FREE daily email newsletter.
